In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Rakuten Aspyrian raises $150mm via Series C round

Executive Summary

Rakuten Aspyrian Inc. (formerly known as Aspyrian Therapeutics) raised $150mm through its Series C round led by company chairman and CEO of Rakuten Inc., Hiroshi Mikitani. The company is developing photoimmunotherapies for cancer and will use the Series C funds to advance lead compound ASP1929 into Phase III trials by the end of 2018 for recurrent head and neck squamous cell carcinomas. Funds will also go towards manufacturing scale-up for future commercialization of the candidate, build-up of commercial operations to support launching ASP1929 in the US, Europe, and Japan, and potential expansion of research for the candidate in other cancers.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies